Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection
We investigated changes in the interferon-[gamma] levels before and after treatment of latent tuberculosis infection (LTBI) using QuantiFERON-TB Gold Plus (QFT-Plus) and QuantiFERON-TB Gold In-Tube (QFT-GIT) assays. The objective was to assess whether QFT-Plus could serve as a biomarker of LTBI trea...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-06, Vol.15 (6), p.e0234700-e0234700 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0234700 |
|---|---|
| container_issue | 6 |
| container_start_page | e0234700 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Kim, Ock-Hwa Jo, Kyung-Wook Park, Shinhee Jo, Yong-Ha Kim, Mi-Na Sung, Heungsup Shim, Tae Sun Caylà, Joan A Wilkinson, Katalin Andrea |
| description | We investigated changes in the interferon-[gamma] levels before and after treatment of latent tuberculosis infection (LTBI) using QuantiFERON-TB Gold Plus (QFT-Plus) and QuantiFERON-TB Gold In-Tube (QFT-GIT) assays. The objective was to assess whether QFT-Plus could serve as a biomarker of LTBI treatment response. We prospectively enrolled 44 individuals whose baseline QFT-GIT and QFT-Plus showed positive results at a tertiary referral center in South Korea between March 2017 and March 2018. The results of the QFT-Plus assay were defined as positive if either or both of the antigen tubes (TB1 and/or TB2) were positive. After LTBI treatment, both tests were repeated. The mean age of the participants was 47.6 years. The QFT-GIT and QFT-Plus assays revealed positive results in 42/44 (95.5%) and 41/44 (93.2%) participants after LTBI treatment, showing overall agreement of 93.2%, with a Cohen's kappa value of 0.37 (fair agreement). The differences between pre- and post-LTBI treatment interferon-[gamma] levels were measured using the QFT-GIT and QFT-Plus assays. No significant differences were noted among the 3 values: the median difference in interferon-[gamma] value with QFT-GIT, QFT-Plus TB1, and QFT-Plus TB2 was 0.211 IU/mL (IQR, -0.337-3.347), 0.025 IU/mL (IQR, -0.338-1.368), and 0.180 IU/mL (IQR, -0.490-2.278), respectively (P = 0.401). The change in interferon-[gamma] levels before and after LTBI treatment measured using the QFT-Plus assay showed a similar trend to that of the QFT-GIT assay. Considering that the QFT-GIT assay is not a useful biomarker of LTBI treatment response, QFT-Plus also appears not to be useful for this purpose. |
| doi_str_mv | 10.1371/journal.pone.0234700 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2413948481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A626791080</galeid><doaj_id>oai_doaj_org_article_2bd91a949d37488e86617d3303a4b45d</doaj_id><sourcerecordid>A626791080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c669t-83d4396b6258b4f360f6dfe88727bc56060af3e663266e8af07f94f9eb22e7a3</originalsourceid><addsrcrecordid>eNqNk9Fu0zAUhiMEYmPwBkhYQkJwkeLYrh3fII1qG5UmCqPi1nKS4zaTGxfbqdiT8Lq4a0AL6gXyha3j7_zH55dPlr0s8KSgonh_63rfaTvZug4mmFAmMH6UnRaSkpwTTB8_OJ9kz0K4xXhKS86fZieUTBkjmJ9mv2Zus9W-Da5DzqC4BlSvdbcC1Hboa6-72F5e3Cw-58uP6MrZBn2xfUC6a45ezrt82VeAPITexsSZCB5tPewgsTvY63u9vUPGeWR1TFEUU4Kve-tCG1JRA3VsXfc8e2K0DfBi2M-y5eXFcvYpv15czWfn13nNuYx5SRtGJa84mZYVM5RjwxsDZSmIqOopxxxrQ4FzSjiHUhssjGRGQkUICE3PslcH2W2qrwZLgyKsoJKVrCwSMT8QjdO3auvbjfZ3yulW3QecXyntY1tbUKRqZKElkw0VrCwheV2IhlJMNavYtElaH4ZqfbWBpk7te21HouObrl2rldspQaSgXCSBt4OAdz96CFFt2lCDtboD19-_mzHMJeUJff0Pery7gVrp1EBy36W69V5UnXPChSxwiRM1OUKl1cCmrdP_M22KjxLejRISE-FnXOk-BDX_dvP_7OL7mH3zgF2DtnEdnO33PyaMQXYAa-9C8GD-mlxgtR-fP26o_fioYXzobzb0Cw4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2413948481</pqid></control><display><type>article</type><title>Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Kim, Ock-Hwa ; Jo, Kyung-Wook ; Park, Shinhee ; Jo, Yong-Ha ; Kim, Mi-Na ; Sung, Heungsup ; Shim, Tae Sun ; Caylà, Joan A ; Wilkinson, Katalin Andrea</creator><contributor>Wilkinson, Katalin Andrea</contributor><creatorcontrib>Kim, Ock-Hwa ; Jo, Kyung-Wook ; Park, Shinhee ; Jo, Yong-Ha ; Kim, Mi-Na ; Sung, Heungsup ; Shim, Tae Sun ; Caylà, Joan A ; Wilkinson, Katalin Andrea ; Wilkinson, Katalin Andrea</creatorcontrib><description>We investigated changes in the interferon-[gamma] levels before and after treatment of latent tuberculosis infection (LTBI) using QuantiFERON-TB Gold Plus (QFT-Plus) and QuantiFERON-TB Gold In-Tube (QFT-GIT) assays. The objective was to assess whether QFT-Plus could serve as a biomarker of LTBI treatment response. We prospectively enrolled 44 individuals whose baseline QFT-GIT and QFT-Plus showed positive results at a tertiary referral center in South Korea between March 2017 and March 2018. The results of the QFT-Plus assay were defined as positive if either or both of the antigen tubes (TB1 and/or TB2) were positive. After LTBI treatment, both tests were repeated. The mean age of the participants was 47.6 years. The QFT-GIT and QFT-Plus assays revealed positive results in 42/44 (95.5%) and 41/44 (93.2%) participants after LTBI treatment, showing overall agreement of 93.2%, with a Cohen's kappa value of 0.37 (fair agreement). The differences between pre- and post-LTBI treatment interferon-[gamma] levels were measured using the QFT-GIT and QFT-Plus assays. No significant differences were noted among the 3 values: the median difference in interferon-[gamma] value with QFT-GIT, QFT-Plus TB1, and QFT-Plus TB2 was 0.211 IU/mL (IQR, -0.337-3.347), 0.025 IU/mL (IQR, -0.338-1.368), and 0.180 IU/mL (IQR, -0.490-2.278), respectively (P = 0.401). The change in interferon-[gamma] levels before and after LTBI treatment measured using the QFT-Plus assay showed a similar trend to that of the QFT-GIT assay. Considering that the QFT-GIT assay is not a useful biomarker of LTBI treatment response, QFT-Plus also appears not to be useful for this purpose.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0234700</identifier><identifier>PMID: 32544206</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Antigens ; Antitubercular agents ; Assaying ; Biology and Life Sciences ; Biomarkers ; Critical care ; Drug therapy ; Gold ; Infections ; Interferon ; Interferon gamma release tests ; Laboratories ; Lymphocytes ; Medical schools ; Medicine ; Medicine and Health Sciences ; Peptides ; Prognosis ; Tuberculosis ; Tubes ; γ-Interferon</subject><ispartof>PloS one, 2020-06, Vol.15 (6), p.e0234700-e0234700</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Kim et al 2020 Kim et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c669t-83d4396b6258b4f360f6dfe88727bc56060af3e663266e8af07f94f9eb22e7a3</citedby><cites>FETCH-LOGICAL-c669t-83d4396b6258b4f360f6dfe88727bc56060af3e663266e8af07f94f9eb22e7a3</cites><orcidid>0000-0002-5783-6795 ; 0000-0001-6653-816X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297367/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297367/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2929,23868,27926,27927,53793,53795</link.rule.ids></links><search><contributor>Wilkinson, Katalin Andrea</contributor><creatorcontrib>Kim, Ock-Hwa</creatorcontrib><creatorcontrib>Jo, Kyung-Wook</creatorcontrib><creatorcontrib>Park, Shinhee</creatorcontrib><creatorcontrib>Jo, Yong-Ha</creatorcontrib><creatorcontrib>Kim, Mi-Na</creatorcontrib><creatorcontrib>Sung, Heungsup</creatorcontrib><creatorcontrib>Shim, Tae Sun</creatorcontrib><creatorcontrib>Caylà, Joan A</creatorcontrib><creatorcontrib>Wilkinson, Katalin Andrea</creatorcontrib><title>Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection</title><title>PloS one</title><description>We investigated changes in the interferon-[gamma] levels before and after treatment of latent tuberculosis infection (LTBI) using QuantiFERON-TB Gold Plus (QFT-Plus) and QuantiFERON-TB Gold In-Tube (QFT-GIT) assays. The objective was to assess whether QFT-Plus could serve as a biomarker of LTBI treatment response. We prospectively enrolled 44 individuals whose baseline QFT-GIT and QFT-Plus showed positive results at a tertiary referral center in South Korea between March 2017 and March 2018. The results of the QFT-Plus assay were defined as positive if either or both of the antigen tubes (TB1 and/or TB2) were positive. After LTBI treatment, both tests were repeated. The mean age of the participants was 47.6 years. The QFT-GIT and QFT-Plus assays revealed positive results in 42/44 (95.5%) and 41/44 (93.2%) participants after LTBI treatment, showing overall agreement of 93.2%, with a Cohen's kappa value of 0.37 (fair agreement). The differences between pre- and post-LTBI treatment interferon-[gamma] levels were measured using the QFT-GIT and QFT-Plus assays. No significant differences were noted among the 3 values: the median difference in interferon-[gamma] value with QFT-GIT, QFT-Plus TB1, and QFT-Plus TB2 was 0.211 IU/mL (IQR, -0.337-3.347), 0.025 IU/mL (IQR, -0.338-1.368), and 0.180 IU/mL (IQR, -0.490-2.278), respectively (P = 0.401). The change in interferon-[gamma] levels before and after LTBI treatment measured using the QFT-Plus assay showed a similar trend to that of the QFT-GIT assay. Considering that the QFT-GIT assay is not a useful biomarker of LTBI treatment response, QFT-Plus also appears not to be useful for this purpose.</description><subject>Antigens</subject><subject>Antitubercular agents</subject><subject>Assaying</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Critical care</subject><subject>Drug therapy</subject><subject>Gold</subject><subject>Infections</subject><subject>Interferon</subject><subject>Interferon gamma release tests</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Medical schools</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Peptides</subject><subject>Prognosis</subject><subject>Tuberculosis</subject><subject>Tubes</subject><subject>γ-Interferon</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9Fu0zAUhiMEYmPwBkhYQkJwkeLYrh3fII1qG5UmCqPi1nKS4zaTGxfbqdiT8Lq4a0AL6gXyha3j7_zH55dPlr0s8KSgonh_63rfaTvZug4mmFAmMH6UnRaSkpwTTB8_OJ9kz0K4xXhKS86fZieUTBkjmJ9mv2Zus9W-Da5DzqC4BlSvdbcC1Hboa6-72F5e3Cw-58uP6MrZBn2xfUC6a45ezrt82VeAPITexsSZCB5tPewgsTvY63u9vUPGeWR1TFEUU4Kve-tCG1JRA3VsXfc8e2K0DfBi2M-y5eXFcvYpv15czWfn13nNuYx5SRtGJa84mZYVM5RjwxsDZSmIqOopxxxrQ4FzSjiHUhssjGRGQkUICE3PslcH2W2qrwZLgyKsoJKVrCwSMT8QjdO3auvbjfZ3yulW3QecXyntY1tbUKRqZKElkw0VrCwheV2IhlJMNavYtElaH4ZqfbWBpk7te21HouObrl2rldspQaSgXCSBt4OAdz96CFFt2lCDtboD19-_mzHMJeUJff0Pery7gVrp1EBy36W69V5UnXPChSxwiRM1OUKl1cCmrdP_M22KjxLejRISE-FnXOk-BDX_dvP_7OL7mH3zgF2DtnEdnO33PyaMQXYAa-9C8GD-mlxgtR-fP26o_fioYXzobzb0Cw4</recordid><startdate>20200616</startdate><enddate>20200616</enddate><creator>Kim, Ock-Hwa</creator><creator>Jo, Kyung-Wook</creator><creator>Park, Shinhee</creator><creator>Jo, Yong-Ha</creator><creator>Kim, Mi-Na</creator><creator>Sung, Heungsup</creator><creator>Shim, Tae Sun</creator><creator>Caylà, Joan A</creator><creator>Wilkinson, Katalin Andrea</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5783-6795</orcidid><orcidid>https://orcid.org/0000-0001-6653-816X</orcidid></search><sort><creationdate>20200616</creationdate><title>Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection</title><author>Kim, Ock-Hwa ; Jo, Kyung-Wook ; Park, Shinhee ; Jo, Yong-Ha ; Kim, Mi-Na ; Sung, Heungsup ; Shim, Tae Sun ; Caylà, Joan A ; Wilkinson, Katalin Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c669t-83d4396b6258b4f360f6dfe88727bc56060af3e663266e8af07f94f9eb22e7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antigens</topic><topic>Antitubercular agents</topic><topic>Assaying</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Critical care</topic><topic>Drug therapy</topic><topic>Gold</topic><topic>Infections</topic><topic>Interferon</topic><topic>Interferon gamma release tests</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Medical schools</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Peptides</topic><topic>Prognosis</topic><topic>Tuberculosis</topic><topic>Tubes</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Ock-Hwa</creatorcontrib><creatorcontrib>Jo, Kyung-Wook</creatorcontrib><creatorcontrib>Park, Shinhee</creatorcontrib><creatorcontrib>Jo, Yong-Ha</creatorcontrib><creatorcontrib>Kim, Mi-Na</creatorcontrib><creatorcontrib>Sung, Heungsup</creatorcontrib><creatorcontrib>Shim, Tae Sun</creatorcontrib><creatorcontrib>Caylà, Joan A</creatorcontrib><creatorcontrib>Wilkinson, Katalin Andrea</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Ock-Hwa</au><au>Jo, Kyung-Wook</au><au>Park, Shinhee</au><au>Jo, Yong-Ha</au><au>Kim, Mi-Na</au><au>Sung, Heungsup</au><au>Shim, Tae Sun</au><au>Caylà, Joan A</au><au>Wilkinson, Katalin Andrea</au><au>Wilkinson, Katalin Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection</atitle><jtitle>PloS one</jtitle><date>2020-06-16</date><risdate>2020</risdate><volume>15</volume><issue>6</issue><spage>e0234700</spage><epage>e0234700</epage><pages>e0234700-e0234700</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>We investigated changes in the interferon-[gamma] levels before and after treatment of latent tuberculosis infection (LTBI) using QuantiFERON-TB Gold Plus (QFT-Plus) and QuantiFERON-TB Gold In-Tube (QFT-GIT) assays. The objective was to assess whether QFT-Plus could serve as a biomarker of LTBI treatment response. We prospectively enrolled 44 individuals whose baseline QFT-GIT and QFT-Plus showed positive results at a tertiary referral center in South Korea between March 2017 and March 2018. The results of the QFT-Plus assay were defined as positive if either or both of the antigen tubes (TB1 and/or TB2) were positive. After LTBI treatment, both tests were repeated. The mean age of the participants was 47.6 years. The QFT-GIT and QFT-Plus assays revealed positive results in 42/44 (95.5%) and 41/44 (93.2%) participants after LTBI treatment, showing overall agreement of 93.2%, with a Cohen's kappa value of 0.37 (fair agreement). The differences between pre- and post-LTBI treatment interferon-[gamma] levels were measured using the QFT-GIT and QFT-Plus assays. No significant differences were noted among the 3 values: the median difference in interferon-[gamma] value with QFT-GIT, QFT-Plus TB1, and QFT-Plus TB2 was 0.211 IU/mL (IQR, -0.337-3.347), 0.025 IU/mL (IQR, -0.338-1.368), and 0.180 IU/mL (IQR, -0.490-2.278), respectively (P = 0.401). The change in interferon-[gamma] levels before and after LTBI treatment measured using the QFT-Plus assay showed a similar trend to that of the QFT-GIT assay. Considering that the QFT-GIT assay is not a useful biomarker of LTBI treatment response, QFT-Plus also appears not to be useful for this purpose.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>32544206</pmid><doi>10.1371/journal.pone.0234700</doi><orcidid>https://orcid.org/0000-0002-5783-6795</orcidid><orcidid>https://orcid.org/0000-0001-6653-816X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-06, Vol.15 (6), p.e0234700-e0234700 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2413948481 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS) Journals Open Access; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Antigens Antitubercular agents Assaying Biology and Life Sciences Biomarkers Critical care Drug therapy Gold Infections Interferon Interferon gamma release tests Laboratories Lymphocytes Medical schools Medicine Medicine and Health Sciences Peptides Prognosis Tuberculosis Tubes γ-Interferon |
| title | Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T06%3A18%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20change%20in%20QuantiFERON-TB%20Gold%20Plus%20and%20QuantiFERON-TB%20Gold%20In-Tube%20results%20after%20preventive%20therapy%20for%20latent%20tuberculosis%20infection&rft.jtitle=PloS%20one&rft.au=Kim,%20Ock-Hwa&rft.date=2020-06-16&rft.volume=15&rft.issue=6&rft.spage=e0234700&rft.epage=e0234700&rft.pages=e0234700-e0234700&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0234700&rft_dat=%3Cgale_plos_%3EA626791080%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2413948481&rft_id=info:pmid/32544206&rft_galeid=A626791080&rft_doaj_id=oai_doaj_org_article_2bd91a949d37488e86617d3303a4b45d&rfr_iscdi=true |